Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Lymphoma, Non-Hodgkin 1Leukemia, B-Cell 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × tirabrutinib × Clear all
NCT02457559 2022-03-24

Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies

Gilead Sciences

Phase 1 Completed
29 enrolled 24 charts

Recurrence

NCT01659255 2021-03-16

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Gilead Sciences

Phase 1 Completed
90 enrolled 27 charts
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡